Talphera (TLPH) Interest Expenses (2010 - 2026)

Talphera (TLPH) posted quarterly Interest Expenses of $118000.0 for Q1 2026, down 99.84% quarter-over-quarter from $72.5 million in Q4 2025.

Talphera (TLPH) Interest Expenses (2010 - 2026) Analysis & Trends

Talphera's Interest Expenses history runs 17 years deep, the most recent figure standing at $118000.0 for Q1 2026.

In Q1 2026, Interest Expenses changed N/A year-over-year to $118000.0; the TTM figure through Mar 2026 stood at $118000.0 (changed N/A YoY), while the FY2025 annual figure was $72.5 million, down 29.6% from the prior year.
Interest Expenses for Q1 2026 stood at $118000.0, down from $72.5 million in the prior quarter.
The five-year high for Interest Expenses was $72.5 million in Q4 2025, with the low at -$34000.0 in Q4 2023.
The 5-year median for Interest Expenses is $145500.0 (2022), against an average of $5.4 million.
The sharpest annual moves came in 2023 and 2025: Interest Expenses plunged 119.77% in 2023, then jumped 36143.5% in 2025.
Talphera's Interest Expenses stood at $172000.0 in 2022, then slumped by 119.77% to -$34000.0 in 2023, then surged by 688.24% to $200000.0 in 2024, then surged by 36143.5% to $72.5 million in 2025, then slumped by 99.84% to $118000.0 in 2026.
Business Quant data shows TLPH's Interest Expenses at $118000.0 in Q1 2026, $72.5 million in Q4 2025, and $226000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-400.56 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	2.90 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	120.70 Mn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	2.90 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	59.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Talphera	90.25 Mn	90.25 Mn	-	-

Download Data